The effects of a two-year randomized, controlled trial of whey protein supplementation on bone structure, IGF-1, and urinary calcium excretion in older postmenopausal women

What Was Tested

This randomized controlled trial paper looks at IGF-1 LR3.

Because no long-term randomized, controlled studies have been performed, a two-year study of protein supplementation in 219 healthy ambulant women aged 70 to 80 years was undertaken.

Quantitative computed tomographic (QCT) hip volumetric bone mineral density (vBMD) and a femoral neck engineering strength analysis were undertaken at baseline and at 2 years.

Who Took Part

The abstract describes 219 women taking part.

PubMed indexes the participants as older adults and people over 80, women only.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The women were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

Some women received a placebo instead of IGF-1 LR3, giving a reference point.

Dual-energy X-ray absorptiometric (DXA) hip areal bone mineral density (aBMD), 24-hour urinary calcium excretion, and serum insulin-like growth factor 1 (IGF-1) were measured at baseline and at 1 and 2 years.

What Was Measured

PubMed files the paper under topics including Bone Density, Bone and Bones, Calcium, Diet, Dietary Supplements, Energy Metabolism and Femur Neck.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of IGF-1 LR3 in 219 women.

The publication is from 2011 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.